Compare BBDC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBDC | PHAR |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | Netherlands |
| Employees | 2 | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.8M | 1.0B |
| IPO Year | 2006 | 2020 |
| Metric | BBDC | PHAR |
|---|---|---|
| Price | $9.34 | $11.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.56 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 657.0K | 16.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $18.13 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.97 | $9.62 |
| 52 Week High | $9.92 | $21.34 |
| Indicator | BBDC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 68.39 | 50.01 |
| Support Level | $8.72 | $12.08 |
| Resistance Level | N/A | $13.61 |
| Average True Range (ATR) | 0.20 | 0.72 |
| MACD | 0.10 | 0.17 |
| Stochastic Oscillator | 91.51 | 66.49 |
Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. It employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.